Expert review of anticancer therapy · 2025
Compression therapy for the prevention of taxane-induced peripheral neuropathy in breast cancer: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luna-Rangel Francisco A, González-Bedolla Brenda, Minera-Villagrán Julio César, Córdova-Garza Marlene I, Vázquez-Juárez Daniela, Villarreal-Garza Cynthia
Аннотация
INTRODUCTION: This systematic review and meta-analysis evaluated whether compression therapy prevents chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients receiving taxanes.
METHODS: Randomized controlled trials (RCTs) including breast cancer patients treated with taxanes and reporting CTCAE-graded CIPN were eligible. The primary outcome was grade ≥2 CIPN incidence. Odds ratios (OR) were pooled with a random-effects model; heterogeneity was assessed with I2, and bias with the Cochrane RoB 2.0 tool.
RESULTS: Three RCTs (n = 195) met criteria. Pooled analysis showed compression therapy significantly lowered CIPN incidence versus control (OR 0.33, 95% CI 0.15-0.71, p = 0.004; I2 = 31%). Compared with standard care, compression markedly reduced CIPN (OR 0.24, 95% CI 0.11-0.49, p = 0.0001). No significant benefit was observed versus sham compression (OR 0.76, 95% CI 0.23-2.54, p = 0.66).
CONCLUSIONS: Compression therapy reduced grade ≥2 CIPN in breast cancer patients receiving taxanes, with benefits over standard care but not sham compression, suggesting placebo contributions. Limitations include the small number of available trials and participants. Larger, rigorously sham-controlled studies are required to confirm effectiveness and establish standardized timing and pressure protocols.
REGISTRATION: PROSPERO (CRD420251055184).
METHODS: Randomized controlled trials (RCTs) including breast cancer patients treated with taxanes and reporting CTCAE-graded CIPN were eligible. The primary outcome was grade ≥2 CIPN incidence. Odds ratios (OR) were pooled with a random-effects model; heterogeneity was assessed with I2, and bias with the Cochrane RoB 2.0 tool.
RESULTS: Three RCTs (n = 195) met criteria. Pooled analysis showed compression therapy significantly lowered CIPN incidence versus control (OR 0.33, 95% CI 0.15-0.71, p = 0.004; I2 = 31%). Compared with standard care, compression markedly reduced CIPN (OR 0.24, 95% CI 0.11-0.49, p = 0.0001). No significant benefit was observed versus sham compression (OR 0.76, 95% CI 0.23-2.54, p = 0.66).
CONCLUSIONS: Compression therapy reduced grade ≥2 CIPN in breast cancer patients receiving taxanes, with benefits over standard care but not sham compression, suggesting placebo contributions. Limitations include the small number of available trials and participants. Larger, rigorously sham-controlled studies are required to confirm effectiveness and establish standardized timing and pressure protocols.
REGISTRATION: PROSPERO (CRD420251055184).